Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Standard lipid profile.

Satish R Tiyyagura1, Donald A Smith

  • 1Department of Cardiology, Zena and Michael A. Wiener Cardiovascular Institute, Marie-Josee and Henry R. Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine, New York, NY 10029-6574, USA.

Clinics in Laboratory Medicine
|November 18, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2021
Same author

Minimally Invasive Lateral Retropleural and Retroperitoneal Approaches in Patients with Thoracic and Lumbar Osteomyelitis: Description of the Techniques and a Series of 14 Patients.

World neurosurgery·2020
Same author

Review: In dyslipidemia or atherosclerotic CVD, alirocumab and evolocumab vs control each reduce MI and stroke.

Annals of internal medicine·2019
Same author

Review: Long-chain ω-3 fatty acids have no effect on mortality or overall cardiovascular events.

Annals of internal medicine·2018
Same author

Review: In adults, increasing ω-6 fatty acid intake does not reduce mortality or overall cardiovascular events.

Annals of internal medicine·2018
Same author

A Case of Type I and II Brugada Phenocopy Unmasked in a Patient with Normal Baseline Electrocardiogram (ECG).

The American journal of case reports·2018
Same journal

Advances in Hemostasis Laboratory Testing.

Clinics in laboratory medicine·2026
Same journal

Extracellular Vesicles in Hemostasis.

Clinics in laboratory medicine·2026
Same journal

Thrombin Generation Assay: Ready for Prime Time.

Clinics in laboratory medicine·2026
Same journal

Viscoelastic Testing for the Laboratorian: Recent Advances and Practical Advice.

Clinics in laboratory medicine·2026
Same journal

Practical Recommendations for Harmonization of Hemostasis Testing Across Hospital Sites.

Clinics in laboratory medicine·2026
Same journal

The Role of Hypoxia in Vascular Endothelial Dysfunction and Venous Thromboembolism.

Clinics in laboratory medicine·2026
See all related articles

The standard lipid profile effectively lowers coronary heart disease risk by focusing on low-density lipoprotein (LDL) cholesterol. However, its accuracy is limited in certain conditions, necessitating further research into alternative lipid measures.

Area of Science:

  • Cardiology
  • Clinical Chemistry
  • Public Health

Background:

  • The standard lipid profile, a cornerstone of cardiovascular risk management, has a robust evidence base for guiding lipid-altering therapies.
  • It primarily focuses on low-density lipoprotein (LDL) cholesterol targets, which have demonstrated efficacy in reducing coronary heart disease (CHD) events.

Purpose of the Study:

  • To evaluate the established benefits and inherent limitations of the standard lipid profile in clinical practice.
  • To discuss the need for further research comparing LDL particle concentration and size versus traditional LDL cholesterol goals.

Main Methods:

  • Review of existing scientific evidence and clinical guidelines for lipid management.
  • Analysis of the limitations of the standard lipid profile, including inaccuracies in nonfasting states and in individuals with hypertriglyceridemia.

Related Experiment Videos

  • Discussion of the potential role of LDL particle characteristics in cardiovascular risk assessment.

    • Main Results:

    • The standard lipid profile has been instrumental in reducing coronary heart disease over the past 50 years.
    • Significant limitations exist in accurately measuring LDL cholesterol, particularly in nonfasting individuals and those with elevated triglycerides.
    • Current evidence does not definitively compare the clinical benefits of targeting LDL particle size and concentration against progressively lower LDL cholesterol levels.

    Conclusions:

    • Despite its limitations, the standard lipid profile remains a major public health achievement in cardiovascular disease prevention.
    • Further research is required to determine if targeting LDL particle concentration and size offers superior clinical benefits compared to lowering LDL cholesterol.
    • Clinical practice will likely continue to rely on evolving standard lipid profile goals pending comparative outcome data.